Ronald Reagan Ucla

Type: Teaching hospital
Where: LOS ANGELES, CA
Medicare CCN: 050262
Received: $36,679,869 in 2,668 records, 2020 ($2,606,138 general, $34,073,731 research)
Source: CMS Open Payments search ↗

By year

Program year	Kind	Records	Amount
2020	General payment	362	$2,606,138
2020	Research payment	2,306	$34,073,731

By company

Company	Records	Amount	Years
Merck Sharp & Dohme LLC	446	$4,557,940	2020
Genentech, Inc.	125	$3,287,226	2020
Amgen Inc.	59	$2,980,771	2020
AstraZeneca Pharmaceuticals LP	43	$2,698,116	2020
E.R. Squibb & Sons, L.L.C.	41	$1,928,399	2020
Daiichi Sankyo Inc.	147	$1,716,550	2020
PTC Therapeutics, Inc.	19	$1,065,860	2020
bioMerieux Inc	1	$939,671	2020
EMD Serono, Inc.	81	$857,447	2020
ABBVIE INC.	72	$700,124	2020
Eli Lilly and Company	31	$699,735	2020
Celgene Corporation	10	$698,592	2020
Abbott Laboratories	48	$647,052	2020
Agios Pharmaceuticals, Inc.	33	$625,036	2020
JAZZ PHARMACEUTICALS INC.	6	$590,030	2020
Boston Scientific Corporation	20	$559,329	2020
Roche Products Limited	27	$518,014	2020
Sarepta Therapeutics, Inc.	18	$506,718	2020
SEAGEN INC.	32	$499,169	2020
F. Hoffmann-La Roche AG	7	$483,696	2020
Astellas Pharma Global Development	31	$478,551	2020
Incyte Corporation	227	$476,324	2020
Kite Pharma, Inc.	34	$398,230	2020
Biogen, Inc.	10	$380,940	2020
Janssen Research & Development, LLC	37	$378,688	2020
Karyopharm Therapeutics Inc.	40	$374,448	2020
Takeda Pharmaceuticals U.S.A., Inc.	67	$359,435	2020
Gilead Sciences, Inc.	12	$340,548	2020
Otsuka Pharmaceutical Development & Commercialization, Inc.	2	$300,000	2020
CSL Behring	42	$284,556	2020
Regeneron Pharmaceuticals, Inc.	20	$277,681	2020
Kadmon Corporation LLC	3	$274,753	2020
Varian Medical Systems, Inc.	10	$261,580	2020
PUMA BIOTECHNOLOGY, INC.	8	$245,439	2020
Hoffmann-La Roche Limited	16	$227,566	2020
Alkermes, Inc.	3	$217,796	2020
PORTOLA PHARMACEUTICALS, LLC	10	$217,726	2020
KARL STORZ Endoscopy-America	176	$207,100	2020
AKEBIA THERAPEUTICS INC	2	$194,408	2020
Acerta Pharma LLC	8	$177,294	2020
Pharmacyclics LLC, an AbbVie Company	66	$174,259	2020
Stryker Corporation	7	$150,250	2020
TransMedics, Inc.	5	$147,663	2020
Eisai Inc.	22	$146,924	2020
VIEWRAY TECHNOLOGIES INC	5	$137,289	2020
Alexion Pharmaceuticals, Inc.	4	$121,880	2020
Medical Device Business Services, Inc.	8	$121,083	2020
Medtronic USA, Inc.	5	$112,277	2020
Novartis Gene Therapies, Inc. (fka Avexis, Inc.)	8	$110,605	2020
Edwards Lifesciences Corporation	14	$110,188	2020

By nature of payment

Nature	Records	Amount
Research payment	2,306	$34,073,731
Grant	65	$1,481,439
Education	190	$349,953
Consulting Fee	8	$319,801
Space rental or facility fees (teaching hospital only)	60	$186,187
Gift	15	$134,962
Royalty or License	4	$96,233
Charitable Contribution	8	$24,618
Compensation for services other than consulting, including serving as faculty or as a speaker at a v	12	$12,941

Records

Date	Company	Amount	Nature	Form	Product	Study	Year
2020-12-31	Daiichi Sankyo Inc.	$233,041	Research payment	Cash or cash equivalent	ENHERTU Drug, ONCOLOGY	A Phase II, Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of trastuzumab deruxtecan (DS-8201a) with	2020
2020-12-31	NIDEK CO., LTD.	$32,000	Research payment	In-kind items and services	Device	Evaluation of Mirante.	2020
2020-12-31	AstraZeneca Pharmaceuticals LP	$27,059	Research payment	In-kind items and services	IMFINZI Drug, Oncology	MEDI4736 anti-PD-L1 mab Solid Tumor-MEDI4736 Ph2 Gastr (Treme combo vs mono)	2020
2020-12-31	AstraZeneca Pharmaceuticals LP	$15,851	Research payment	In-kind items and services	IMFINZI Drug, Oncology	A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Co	2020
2020-12-31	KARL STORZ Endoscopy-America	$15,042	Education	In-kind items and services	VITOM 90 DETACHABLE, AUTOCLAVE Device, MICRO/NOTES/MILITARY		2020
2020-12-31	NIDEK CO., LTD.	$9,000	Research payment	In-kind items and services	Device	Evaluation of RS-3000 Advance 2.	2020
2020-12-31	KARL STORZ Endoscopy-America	$7,734	Education	In-kind items and services	VIDEO CART WITH FULL DOOR Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$7,733	Education	In-kind items and services	TELESCOPE,HOPKINS II, 0, ENLARGED VIEW, Device, LAPAROSCOPY		2020
2020-12-31	Acerta Pharma LLC	$7,222	Research payment	In-kind items and services	CALQUENCE Drug, Oncology	A Proof of Concept Study of the Combination of ACP196 and Pembrolizumab in Subjects with Hematologic Malignancies	2020
2020-12-31	KARL STORZ Endoscopy-America	$7,152	Education	In-kind items and services	AIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR1		2020
2020-12-31	KARL STORZ Endoscopy-America	$5,475	Education	In-kind items and services	TELESCOPE,HOPKINS II, 0, ENLARGED VIEW, Device, LAPAROSCOPY		2020
2020-12-31	AstraZeneca Pharmaceuticals LP	$5,342	Research payment	In-kind items and services	TAGRISSO Drug, Oncology	To assess the efficacy and safety of AZD9291 versus Placebo in patients with Epidermal Growth Factor Receptor Mutation P	2020
2020-12-31	KARL STORZ Endoscopy-America	$5,004	Education	In-kind items and services	QUINTUS 45MM ADAPTOR F/ZEISS MICROSCOPE Device, MICRO/NOTES/MILITARY		2020
2020-12-31	AstraZeneca Pharmaceuticals LP	$4,728	Research payment	In-kind items and services	FASENRA Drug, Respiratory	A Multicenter Randomized Double Blind Parallel Group Placebo Controlled Phase 3 Efficacy and Safety Study Of Benralizuma	2020
2020-12-31	KARL STORZ Endoscopy-America	$4,307	Education	In-kind items and services	TRAINER F/SIMULATED LAPAROSCOPIC Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$4,233	Education	In-kind items and services	TRAINER F/SIMULATED LAPAROSCOPIC Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$4,233	Education	In-kind items and services	TRAINER F/SIMULATED LAPAROSCOPIC Device, LAPAROSCOPY		2020
2020-12-31	AstraZeneca UK Limited	$4,149	Research payment	In-kind items and services		The purpose of this study is to characterise longterm safety and tolerability of intravenous anifrolumab A Multicentre R	2020
2020-12-31	AstraZeneca Pharmaceuticals LP	$4,079	Research payment	In-kind items and services		An Open Label, Randomised, Multi Drug, Biomarker Directed, Multi Centre, Multi arm Phase 1b Study in patients with Muscl	2020
2020-12-31	AstraZeneca Pharmaceuticals LP	$3,897	Research payment	In-kind items and services	LYNPARZA Drug, Oncology	A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Pati	2020
2020-12-31	KARL STORZ Endoscopy-America	$3,678	Education	In-kind items and services	TRAINER F/SIMULATED LAPAROSCOPIC Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$3,678	Education	In-kind items and services	TRAINER F/SIMULATED LAPAROSCOPIC Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$3,519	Education	In-kind items and services	TELESCOPE,HOPKINS II, 0, ENLARGED VIEW, Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$3,498	Education	In-kind items and services	TELESCOPE,HOPKINS II, 0, ENLARGED VIEW, Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$3,498	Education	In-kind items and services	TELESCOPE,HOPKINS II, 0, ENLARGED VIEW, Device, LAPAROSCOPY		2020
2020-12-31	Edwards Lifesciences Corporation	$3,382	Education	In-kind items and services	EV1000 Clinical Platform Device, Minimally Invasive Hemodynamic Monitoring		2020
2020-12-31	AstraZeneca Pharmaceuticals LP	$3,133	Research payment	In-kind items and services	IMFINZI Drug, Oncology	A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with	2020
2020-12-31	KARL STORZ Endoscopy-America	$2,355	Education	In-kind items and services	TRAINER F/SIMULATED LAPAROSCOPIC Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$2,355	Education	In-kind items and services	TRAINER F/SIMULATED LAPAROSCOPIC Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$2,355	Education	In-kind items and services	TRAINER F/SIMULATED LAPAROSCOPIC Device, LAPAROSCOPY		2020
2020-12-31	Edwards Lifesciences Corporation	$2,232	Education	In-kind items and services	EV1000 Clinical Platform Device, Minimally Invasive Hemodynamic Monitoring		2020
2020-12-31	KARL STORZ Endoscopy-America	$1,774	Education	In-kind items and services	TELESCOPE,HOPKINS II, 0, ENLARGED VIEW, Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$1,741	Education	In-kind items and services	TELESCOPE,HOPKINS II, 0, ENLARGED VIEW, Device, LAPAROSCOPY		2020
2020-12-31	Acerta Pharma LLC	$1,565	Research payment	In-kind items and services	CALQUENCE Drug, Oncology	A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreat	2020
2020-12-31	KARL STORZ Endoscopy-America	$1,252	Education	In-kind items and services	VIDEO CART WITH FULL DOOR Device, VIDEOIMAGING		2020
2020-12-31	AstraZeneca UK Limited	$1,170	Research payment	In-kind items and services		A Platform Protocol for the Treatment of Relapsed /Refractory Aggressive Non-Hodgkin's Lymphoma	2020
2020-12-31	AstraZeneca Pharmaceuticals LP	$1,074	Research payment	In-kind items and services		A Biomarker-Directed Phase 2 Platform Study in Patients with Advanced Non-Small Cell Lung Cancer whose Disease has Progr	2020
2020-12-31	KARL STORZ Endoscopy-America	$1,015	Education	In-kind items and services	HANDLE, ONLY, PLASTIC W/O RATCHET Device, LAPAROSCOPY		2020
2020-12-31	AstraZeneca UK Limited	$1,003	Research payment	In-kind items and services	IMFINZI Drug, Oncology	A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresect	2020
2020-12-31	Acerta Pharma LLC	$996	Research payment	In-kind items and services	CALQUENCE Drug, Oncology	A Proof of Concept Study of the Combination of ACP196 and ACP319 in Subjects with Bcell Malignancies	2020
2020-12-31	KARL STORZ Endoscopy-America	$920	Education	In-kind items and services	HANDLE, ONLY, PLASTIC W/O RATCHET Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$901	Education	In-kind items and services	TRAINER F/SIMULATED LAPAROSCOPIC Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$775	Education	In-kind items and services	QUINTUS 45MM ADAPTOR F/ZEISS MICROSCOPE Device, MICRO/NOTES/MILITARY		2020
2020-12-31	KARL STORZ Endoscopy-America	$764	Education	In-kind items and services	ARTICULATED STAND, L-SHAPED, LONG Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$695	Education	In-kind items and services	TELESCOPE,HOPKINS II, 0, ENLARGED VIEW, Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$616	Education	In-kind items and services	HANDLE, ONLY, PLASTIC W/O RATCHET Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$616	Education	In-kind items and services	HANDLE, ONLY, PLASTIC W/O RATCHET Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$577	Education	In-kind items and services	TRAINER F/SIMULATED LAPAROSCOPIC Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$527	Education	In-kind items and services	HANDLE, ONLY, PLASTIC W/O RATCHET Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$479	Education	In-kind items and services	TELESCOPE,HOPKINS II, 0, ENLARGED VIEW, Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$479	Education	In-kind items and services	TELESCOPE,HOPKINS II, 0, ENLARGED VIEW, Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$479	Education	In-kind items and services	TELESCOPE,HOPKINS II, 0, ENLARGED VIEW, Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$479	Education	In-kind items and services	TELESCOPE,HOPKINS II, 0, ENLARGED VIEW, Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$479	Education	In-kind items and services	TELESCOPE,HOPKINS II, 0, ENLARGED VIEW, Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$479	Education	In-kind items and services	TELESCOPE,HOPKINS II, 0, ENLARGED VIEW, Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$479	Education	In-kind items and services	TELESCOPE,HOPKINS II, 0, ENLARGED VIEW, Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$479	Education	In-kind items and services	TELESCOPE,HOPKINS II, 0, ENLARGED VIEW, Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$479	Education	In-kind items and services	TELESCOPE,HOPKINS II, 0, ENLARGED VIEW, Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$460	Education	In-kind items and services	HANDLE, ONLY, PLASTIC W/O RATCHET Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$450	Education	In-kind items and services	TELESCOPE,HOPKINS II, 0, ENLARGED VIEW, Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$408	Education	In-kind items and services	HANDLE, ONLY, PLASTIC W/O RATCHET Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$408	Education	In-kind items and services	HANDLE, ONLY, PLASTIC W/O RATCHET Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$390	Education	In-kind items and services	VIDEO CART WITH FULL DOOR Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$376	Education	In-kind items and services	HANDLE, ONLY, PLASTIC W/O RATCHET Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$345	Education	In-kind items and services	TELESCOPE,HOPKINS II, 0, ENLARGED VIEW, Device, LAPAROSCOPY		2020
2020-12-31	AstraZeneca Pharmaceuticals LP	$296	Research payment	In-kind items and services		Study of MEDI4736 Durvalumab With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer	2020
2020-12-31	KARL STORZ Endoscopy-America	$280	Education	In-kind items and services	TELESCOPE,HOPKINS II, 0, ENLARGED VIEW, Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$263	Education	In-kind items and services	HANDLE, ONLY, PLASTIC W/O RATCHET Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$263	Education	In-kind items and services	HANDLE, ONLY, PLASTIC W/O RATCHET Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$240	Education	In-kind items and services	VIDEO CART WITH FULL DOOR Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$210	Education	In-kind items and services	TELESCOPE,HOPKINS II, 0, ENLARGED VIEW, Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$202	Education	In-kind items and services	TELESCOPE,HOPKINS II, 0, ENLARGED VIEW, Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$184	Education	In-kind items and services	TELESCOPE,HOPKINS II, 0, ENLARGED VIEW, Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$173	Education	In-kind items and services	HANDLE, ONLY, PLASTIC W/O RATCHET Device, LAPAROSCOPY		2020
2020-12-31	AstraZeneca Pharmaceuticals LP	$172	Research payment	In-kind items and services		A Lead in Phase II Multicentre Randomised Study of AZD1775 in Women with Platinum Resistant High Grade Serous Ovarian Ca	2020
2020-12-31	KARL STORZ Endoscopy-America	$157	Education	In-kind items and services	HIGH PRESSURE HOSE F/26410005 LAPAROFLAT Device, OTHER MISC		2020
2020-12-31	KARL STORZ Endoscopy-America	$150	Education	In-kind items and services	HIGH PRESSURE HOSE F/26410005 LAPAROFLAT Device, OTHER MISC		2020
2020-12-31	KARL STORZ Endoscopy-America	$144	Education	In-kind items and services	TELESCOPE,HOPKINS II, 0, ENLARGED VIEW, Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$135	Education	In-kind items and services	TELESCOPE,HOPKINS II, 0, ENLARGED VIEW, Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$131	Education	In-kind items and services	HANDLE, ONLY, PLASTIC W/O RATCHET Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$131	Education	In-kind items and services	HANDLE, ONLY, PLASTIC W/O RATCHET Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$131	Education	In-kind items and services	HANDLE, ONLY, PLASTIC W/O RATCHET Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$131	Education	In-kind items and services	HANDLE, ONLY, PLASTIC W/O RATCHET Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$127	Education	In-kind items and services	TELESCOPE,HOPKINS II, 0, ENLARGED VIEW, Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$127	Education	In-kind items and services	TELESCOPE,HOPKINS II, 0, ENLARGED VIEW, Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$127	Education	In-kind items and services	TELESCOPE,HOPKINS II, 0, ENLARGED VIEW, Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$117	Education	In-kind items and services	HANDLE, ONLY, PLASTIC W/O RATCHET Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$115	Education	In-kind items and services	TELESCOPE,HOPKINS II, 0, ENLARGED VIEW, Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$105	Education	In-kind items and services	ARTICULATED STAND, L-SHAPED, LONG Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$81	Education	In-kind items and services	TELESCOPE,HOPKINS II, 0, ENLARGED VIEW, Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$75	Education	In-kind items and services	HIGH PRESSURE HOSE F/26410005 LAPAROFLAT Device, OTHER MISC		2020
2020-12-31	KARL STORZ Endoscopy-America	$67	Education	In-kind items and services	TELESCOPE,HOPKINS II, 0, ENLARGED VIEW, Device, LAPAROSCOPY		2020
2020-12-31	Abbott Laboratories	$60	Research payment	In-kind items and services	Esprit BTK Everolimus Eluting Resorbable Scaffold System Device, Cardiac Arrhythmias and Heart Failure	LIFE-BTK Randomized Controlled Trial	2020
2020-12-31	KARL STORZ Endoscopy-America	$46	Education	In-kind items and services	VIDEO CART WITH FULL DOOR Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$24	Education	In-kind items and services	VIDEO CART WITH FULL DOOR Device, VIDEOIMAGING		2020
2020-12-31	KARL STORZ Endoscopy-America	$21	Education	In-kind items and services	VIDEO CART WITH FULL DOOR Device, VIDEOIMAGING		2020
2020-12-31	Aimmune Therapeutics, Inc.	$18	Research payment	Cash or cash equivalent	PALFORZIA Biological, ALLERGY	A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS	2020
2020-12-31	KARL STORZ Endoscopy-America	$9	Education	In-kind items and services	TELESCOPE,HOPKINS II, 0, ENLARGED VIEW, Device, LAPAROSCOPY		2020
2020-12-31	KARL STORZ Endoscopy-America	$2	Education	In-kind items and services	VIDEO CART WITH FULL DOOR Device, VIDEOIMAGING		2020
2020-12-31	AstraZeneca Pharmaceuticals LP	$2	Research payment	In-kind items and services		A Phase III Randomized Multi Center OpenLabel Comparative Global Study to Determine the Efficacy of Durvalumab or Durval	2020
2020-12-30	ABBVIE INC.	$26,239	Research payment	Cash or cash equivalent		M14-239	2020
2020-12-30	Daiichi Sankyo Inc.	$2,338	Research payment	Cash or cash equivalent	Enhertu Drug, Oncology	DS8201-A-U201	2020
2020-12-30	Daiichi Sankyo Inc.	$2,338	Research payment	Cash or cash equivalent	Enhertu Drug, Oncology	DS8201-A-U201	2020
2020-12-30	Daiichi Sankyo Inc.	$2,338	Research payment	Cash or cash equivalent	Enhertu Drug, Oncology	DS8201-A-U201	2020
2020-12-30	Daiichi Sankyo Inc.	$2,338	Research payment	Cash or cash equivalent	Enhertu Drug, Oncology	DS8201-A-U201	2020
2020-12-30	ABBVIE INC.	$1,159	Research payment	Cash or cash equivalent	VENCLEXTA Drug, ONCOLOGY	M19-388	2020
2020-12-29	KARL STORZ Endoscopy-America	$17,174	Education	In-kind items and services	VISITOR1 CART PACKAGED, W/ HEAD, SW, 2.0 Device, OR1		2020
2020-12-28	Merck Sharp & Dohme LLC	$45,597	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 1,2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or P	2020
2020-12-28	Merck Sharp & Dohme LLC	$13,027	Research payment	In-kind items and services	MK-1454 Drug, ONCOLOGY	A Phase 2 Study in First Line Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma to Evaluate In	2020
2020-12-28	ABBVIE INC.	$1,000	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	HUMIRA Biological, IMMUNOLOGY		2020
2020-12-25	Amgen Inc.	$37,221	Research payment	Cash or cash equivalent		AMG 596 - Gioblastoma_20160132	2020
2020-12-24	Eisai Inc.	$4,436	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	An Open-Label Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Subjects with Hepatocellular Carcinoma	2020
2020-12-24	Eisai Inc.	$124	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	An Open-Label Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Subjects with Hepatocellular Carcinoma	2020
2020-12-23	Gilead Sciences, Inc.	$7,228	Research payment	Cash or cash equivalent	Veklury Drug, COVID-19	A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesi	2020
2020-12-23	ABBVIE INC.	$6,220	Research payment	Cash or cash equivalent		M14-006	2020
2020-12-23	ABBVIE INC.	$6,220	Research payment	Cash or cash equivalent		M14-006	2020
2020-12-22	Agios Pharmaceuticals, Inc.	$69,867	Research payment	Cash or cash equivalent	TIBSOVO Drug, Oncology	A Phase I, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolida	2020
2020-12-22	Agios Pharmaceuticals, Inc.	$56,826	Research payment	Cash or cash equivalent	TIBSOVO Drug, Oncology	A Phase I, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolida	2020
2020-12-22	Roche Products Limited	$55,792	Research payment	Cash or cash equivalent	Actemra Biological, Immunology	COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY	2020
2020-12-22	Agios Pharmaceuticals, Inc.	$55,519	Research payment	Cash or cash equivalent	TIBSOVO Drug, Oncology	A Phase I, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolida	2020
2020-12-22	Agios Pharmaceuticals, Inc.	$44,070	Research payment	Cash or cash equivalent	TIBSOVO Drug, Oncology	A Phase I, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolida	2020
2020-12-22	Agios Pharmaceuticals, Inc.	$40,628	Research payment	Cash or cash equivalent	TIBSOVO Drug, Oncology	A Phase I, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolida	2020
2020-12-22	Radius Health, Inc.	$32,950	Research payment	Cash or cash equivalent		Abaloparatide for the Treatment of Osteonecrosis of the Jaws	2020
2020-12-22	Boston Scientific Corporation	$16,500	Research payment	Cash or cash equivalent	EMBOZENE Device, EMBOLICS	GAE for knee arthritis	2020
2020-12-22	Agios Pharmaceuticals, Inc.	$14,364	Research payment	Cash or cash equivalent	TIBSOVO Drug, Oncology	A Phase I, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolida	2020
2020-12-22	Boston Scientific Corporation	$3,260	Research payment	Cash or cash equivalent	EKOSONIC Device, PERIPHERAL VASCULAR	KNOCOUT PE	2020
2020-12-22	Daiichi Sankyo Inc.	$2,071	Research payment	Cash or cash equivalent	Enhertu Drug, Oncology	DS8201-A-U303	2020
2020-12-22	Agios Pharmaceuticals, Inc.	$1,426	Research payment	Cash or cash equivalent	TIBSOVO Drug, Oncology	A Phase I, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolida	2020
2020-12-22	Glaukos Corporation	$1,250	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	iStent inject Trabecular Micro-Bypass Stent System Device, Glaucoma		2020
2020-12-22	Roche Products Limited	$945	Research payment	Cash or cash equivalent	Actemra Biological, Immunology	COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY	2020
2020-12-22	Roche Products Limited	$630	Research payment	Cash or cash equivalent	Actemra Biological, Immunology	COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY	2020
2020-12-22	Roche Products Limited	$630	Research payment	Cash or cash equivalent	Actemra Biological, Immunology	COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY	2020
2020-12-21	Immunomedics, Inc.	$10,703	Research payment	Cash or cash equivalent	Trodelvy Drug, Oncology	IMMU-132-05	2020
2020-12-21	Janssen Research & Development, LLC	$1,652	Research payment	Cash or cash equivalent		A Prospective, Open-Label, Active-Controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Effic	2020
2020-12-21	Cook Research Incorporated	$1,391	Research payment	Cash or cash equivalent		(13-003) A Double-blind, Randomized, Controlled Trial Comparing the Safety and Efficacy of AMDC-USR with Placebo in Fema	2020
2020-12-21	KARL STORZ Endoscopy-America	$59	Education	In-kind items and services	VITOM 90 DETACHABLE, AUTOCLAVE Device, MICRO/NOTES/MILITARY		2020
2020-12-18	KARL STORZ Endoscopy-America	$93	Education	In-kind items and services	VITOM 90 DETACHABLE, AUTOCLAVE Device, MICRO/NOTES/MILITARY		2020
2020-12-17	Regeneron Pharmaceuticals, Inc.	$24,596	Research payment	Cash or cash equivalent	EYLEA Biological, OPHTHALMOLOGY	MICROVASCULAR STRUCTURE AND MORPHOLOGY OF NEOVASCULAR MEMBRANES IN AGE RELATED MACULAR DEGENERATION (AMD) AFTER INTRAVIT	2020
2020-12-17	Sarepta Therapeutics, Inc.	$21,137	Research payment	Cash or cash equivalent		SRP-9001-102	2020
2020-12-17	Merck Sharp & Dohme LLC	$19,541	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cis	2020
2020-12-17	MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA, INC.	$15,415	Research payment	Cash or cash equivalent		SAFETY STUDY OF ORAL EDARAVONE ADMINISTERED IN SUBJECTS WITH ALS	2020
2020-12-17	Daiichi Sankyo Inc.	$5,481	Research payment	Cash or cash equivalent	Enhertu Drug, Oncology		2020
2020-12-17	Merck Sharp & Dohme LLC	$720	Research payment	In-kind items and services	MK-4280 Biological, ONCOLOGY	A Phase 1,Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab MK-34	2020
2020-12-17	Deciphera Pharmaceuticals Inc.	$200	Research payment	Cash or cash equivalent	QINLOCK Drug, ONCOLOGY	INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN	2020
2020-12-16	SEAGEN INC.	$46,354	Research payment	Cash or cash equivalent	TUKYSA Drug, Oncology	Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas	2020
2020-12-16	Daiichi Sankyo Inc.	$31,350	Research payment	Cash or cash equivalent			2020
2020-12-16	Daiichi Sankyo Inc.	$22,325	Research payment	Cash or cash equivalent			2020
2020-12-16	ABBVIE INC.	$5,481	Research payment	Cash or cash equivalent		M14-239	2020
2020-12-16	Daiichi Sankyo Inc.	$4,292	Research payment	Cash or cash equivalent			2020
2020-12-16	Genentech, Inc.	$2,528	Research payment	Cash or cash equivalent	Non-Covered Product Drug, None	PORT DELIVERY SYSTEM OF RANIZIBUMAB EXTENSION STUDY	2020
2020-12-16	Deciphera Pharmaceuticals Inc.	$44	Research payment	Cash or cash equivalent		A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS	2020
2020-12-15	SEAGEN INC.	$23,125	Research payment	In-kind items and services	TUKYSA Drug, Oncology	Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas	2020
2020-12-15	Genentech, Inc.	$18,577	Research payment	Cash or cash equivalent	Zelboraf Biological, BioOncology	A PH 1B ATEZOLIZUMAB WITH VEMURAFENIB OR WITH VEMURAFENIB AND COBIMETINIB IN BRAF METASTATIC MELANO	2020
2020-12-15	SEAGEN INC.	$15,416	Research payment	In-kind items and services	TUKYSA Drug, Oncology	Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas	2020
2020-12-15	BIOTRONIK INC.	$3,750	Grant	Cash or cash equivalent			2020
2020-12-15	Genentech, Inc.	$813	Research payment	Cash or cash equivalent	Non-Covered Product Drug, None	GDC 0068 CHEMOTHERAPY IN 1L GASTRIC CANCER	2020
2020-12-15	CSL Behring	$693	Research payment	Cash or cash equivalent		A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a	2020
2020-12-15	Pharmacyclics LLC, an AbbVie Company	$477	Research payment	Cash or cash equivalent	Imbruvica Drug, Oncology	PCYC-1145-LT	2020
2020-12-15	KARL STORZ Endoscopy-America	$120	Education	In-kind items and services	VITOM 90 DETACHABLE, AUTOCLAVE Device, MICRO/NOTES/MILITARY		2020
2020-12-15	CSL Behring	$50	Research payment	Cash or cash equivalent		A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a	2020
2020-12-14	KARL STORZ Endoscopy-America	$665	Education	In-kind items and services	VITOM 90 DETACHABLE, AUTOCLAVE Device, MICRO/NOTES/MILITARY		2020
2020-12-14	KARL STORZ Endoscopy-America	$46	Education	In-kind items and services	VITOM 90 DETACHABLE, AUTOCLAVE Device, MICRO/NOTES/MILITARY		2020
2020-12-11	PTC Therapeutics, Inc.	$9,032	Research payment	Cash or cash equivalent		AN OPEN-LABEL, SAFETY STUDY FOR PREVIOUSLY TREATED ATALUREN PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY	2020
2020-12-11	PTC Therapeutics, Inc.	$4,814	Research payment	Cash or cash equivalent		AN OPEN-LABEL, SAFETY STUDY FOR PREVIOUSLY TREATED ATALUREN PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY	2020
2020-12-11	Genentech, Inc.	$3,150	Research payment	Cash or cash equivalent	TECENTRIQ Biological, BioOncology	PHASE III STUDY IN ADJUVANT THERAPY IN RENAL CELL CARCINOMA PATIENTS	2020
2020-12-11	KARL STORZ Endoscopy-America	$392	Education	In-kind items and services	VITOM 90 DETACHABLE, AUTOCLAVE Device, MICRO/NOTES/MILITARY		2020
2020-12-11	KARL STORZ Endoscopy-America	$249	Education	In-kind items and services	VITOM 90 DETACHABLE, AUTOCLAVE Device, MICRO/NOTES/MILITARY		2020
2020-12-11	W. L. Gore & Associates, Inc.	$126	Research payment	Cash or cash equivalent	Product in Development Device, Devices	GORE CARDIOFORM ASD Occluder Clinical Study: A Study to evaluate safety and efficacy in the treatment of transcatheter c	2020
2020-12-10	Stryker Corporation	$103,000	Research payment	Cash or cash equivalent	TREVO Device, MICROCATHETERSTENTRIEVER	TREVO REGISTRY	2020
2020-12-10	Alexion Pharmaceuticals, Inc.	$24,906	Research payment	Cash or cash equivalent		Efficacy and Safety of ALXN1840 (Formerly Named WTX101) Administered for 48 Weeks Versus Standard of Care in Patients Wi	2020
2020-12-10	Agios Pharmaceuticals, Inc.	$24,306	Research payment	Cash or cash equivalent		A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Vorasidenib in Subjects with Recurrent, No	2020
2020-12-10	Amgen Inc.	$14,260	Research payment	Cash or cash equivalent	Repatha Biological, Cardiology	Optical Coherence Tomography (OCT) Study	2020
2020-12-10	Pharmacyclics LLC, an AbbVie Company	$11,611	Research payment	Cash or cash equivalent	Imbruvica Drug, Oncology	PCYC-1141-CA	2020
2020-12-10	Incyte Corporation	$11,527	Research payment	Cash or cash equivalent		An Open Label Phase 1b Study of the Safety, Tolerability, and Preliminary Antitumor Activity of INCB059872 in Participan	2020
2020-12-10	Incyte Corporation	$10,828	Research payment	Cash or cash equivalent		An Open Label Phase 1b Study of the Safety, Tolerability, and Preliminary Antitumor Activity of INCB059872 in Participan	2020
2020-12-10	Edwards Lifesciences Corporation	$10,202	Research payment	Cash or cash equivalent		ALTERRA Early Feasibility (2016-04)	2020
2020-12-10	Incyte Corporation	$9,520	Research payment	Cash or cash equivalent		An Open Label Phase 1b Study of the Safety, Tolerability, and Preliminary Antitumor Activity of INCB059872 in Participan	2020
2020-12-10	BeiGene, Ltd.	$8,442	Research payment	Cash or cash equivalent		A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy and Safety of BGB-A317 versus Sorafenib as F	2020
2020-12-10	ChromaCode, Inc	$8,250	Research payment	Cash or cash equivalent		Analytical Assessment of ChromaCodes HDPCR Multi Drug Resistance Panel RUO using AR Isolate Bank Samples	2020
2020-12-10	EMD Serono, Inc.	$4,663	Research payment	Cash or cash equivalent	M7824 (PD-L1 TRAP)	An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (bintrafusp alfa) versus Pembroliz	2020
2020-12-10	Genentech, Inc.	$1,077	Research payment	Cash or cash equivalent	Rituxan Biological, BioOncology/Immunology	POLARIX	2020
2020-12-10	Aesculap, Inc.	$846	Gift	Cash or cash equivalent			2020
2020-12-10	Aesculap, Inc.	$132	Gift	Cash or cash equivalent			2020
2020-12-10	Aesculap, Inc.	$52	Gift	Cash or cash equivalent			2020
2020-12-09	Genentech, Inc.	$426,943	Research payment	Cash or cash equivalent	Esbriet Biological, Immunology	SCLERODERMA LUNG STUDY III COMBINING PIRFENIDONE WITH MYCOPHENOLATE SLSIII	2020
2020-12-09	Abbott Laboratories	$216,289	Research payment	Cash or cash equivalent	I STAT Hs TnL Device, Diagnostics	Alinity I STAT hsTnl Design Validation Protocol	2020
2020-12-09	Genentech, Inc.	$91,271	Research payment	Cash or cash equivalent	Esbriet Biological, Immunology	SCLERODERMA LUNG STUDY III COMBINING PIRFENIDONE WITH MYCOPHENOLATE SLSIII	2020
2020-12-09	Merck Sharp & Dohme LLC	$58,625	Research payment	In-kind items and services	MK-4280 Biological, ONCOLOGY	A Phase 1,Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab MK-34	2020
2020-12-09	Genentech, Inc.	$48,742	Research payment	Cash or cash equivalent	Actemra Biological, Immunology	CEA TCB PHASE 1B COMBINATION WITH APD L1 STUDY	2020
2020-12-09	SEAGEN INC.	$36,809	Research payment	Cash or cash equivalent	TUKYSA Drug, Oncology	Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas	2020
2020-12-09	Genentech, Inc.	$17,940	Research payment	Cash or cash equivalent	Esbriet Biological, Immunology	SCLERODERMA LUNG STUDY III COMBINING PIRFENIDONE WITH MYCOPHENOLATE SLSIII	2020
2020-12-09	SEAGEN INC.	$1,000	Research payment	Cash or cash equivalent	TUKYSA Drug, Oncology	Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib	2020
2020-12-08	Genentech, Inc.	$26,094	Research payment	Cash or cash equivalent	Actemra Biological, Immunology	CEA TCB PHASE 1B COMBINATION WITH APD L1 STUDY	2020
2020-12-08	Karyopharm Therapeutics Inc.	$10,292	Research payment	Cash or cash equivalent	XPOVIO Drug, Oncology	KCP-330-017A	2020
2020-12-08	Stemline Therapeutics Inc.	$4,221	Research payment	Cash or cash equivalent		STML-401-0314	2020
2020-12-08	Karyopharm Therapeutics Inc.	$3,591	Research payment	Cash or cash equivalent	XPOVIO Drug, Oncology	KCP-330-009	2020
2020-12-08	Roche Products Limited	$2,268	Research payment	Cash or cash equivalent	Actemra Biological, Immunology	COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY	2020
2020-12-08	Karyopharm Therapeutics Inc.	$1,610	Research payment	Cash or cash equivalent	XPOVIO Drug, Oncology	XPORT-COV-1001	2020
2020-12-08	Karyopharm Therapeutics Inc.	$1,553	Research payment	Cash or cash equivalent	XPOVIO Drug, Oncology	XPORT-COV-1001	2020
2020-12-08	KARL STORZ Endoscopy-America	$1,533	Education	In-kind items and services	VITOM 90 DETACHABLE, AUTOCLAVE Device, MICRO/NOTES/MILITARY		2020

The latest 200 records of 2,668.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Los Angeles, CA, county Los Angeles County, CA, state California; placed by its city name.

Measure	Place (city or town) Los Angeles, CA	County Los Angeles County, CA	State California
Population B01003	3,857,263	9,808,667	39,287,377
Population, 2020 census P1	3,898,747	10,014,009	39,538,223
Median age B01002	37.2	38.2	37.9
Under 18 B01001	19.2%	20.6%	22.0%
65 and over B01001	14.2%	15.2%	15.7%
Households B11001	1,439,097	3,416,449	13,548,091
Foreign born B05002	35.7%	33.4%	27.0%
Median household income B19013	$81,939	$90,112	$99,122
Median family income B19113	$94,546	$101,573	$113,346
Per capita income B19301	$47,685	$45,792	$49,513
Poverty rate B17001	16.5%	13.7%	12.0%
Unemployment rate B23025	8.2%	7.3%	6.6%
Civilian labor force B23025	2,128,918	5,200,656	20,068,466
Mean commute (minutes) B08013	30.7	30.4	28.7
Bachelor's degree or higher B15003	38.5%	36.0%	37.1%
Housing units B25001	1,554,332	3,650,466	14,644,735
Owner-occupied B25003	36.0%	45.9%	55.9%
Renters B25003	64.0%	54.1%	44.1%
Median home value B25077	$921,200	$834,200	$734,700
Median gross rent B25064	$1,933	$1,954	$2,036
White, not Hispanic B03002	28.1%	24.7%	33.8%
Black B03002	8.1%	7.4%	5.2%
Hispanic or Latino B03002	47.2%	48.4%	40.2%
Asian B03002	11.9%	14.9%	15.3%
American Indian and Alaska Native B03002	0.1%	0.2%	0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Los Angeles, CA.